Pimavanserin 34 mg + Placebo

Phase 2Recruiting

0 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Intermittent Explosive Disorder

Conditions

Intermittent Explosive Disorder

Trial Timeline

Aug 1, 2024 → Jan 1, 2028

NCT ID

NCT05895513

About Pimavanserin 34 mg + Placebo

Pimavanserin 34 mg + Placebo is a phase 2 stage product being developed by Acadia Pharmaceuticals for Intermittent Explosive Disorder. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05895513. Target conditions include Intermittent Explosive Disorder.

What happened to similar drugs?

1 of 2 similar drugs in Intermittent Explosive Disorder were approved

Approved (1) Terminated (1) Active (0)

✅Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcgAstraZenecaApproved

❌Azithromycin plus chloroquine + sulfadoxine-pyrimethaminePfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05895513	Phase 2	Recruiting	Aug 1, 2024	Jan 1, 2028	Intermittent Explosive Disorder

Competing Products

12 competing products in Intermittent Explosive Disorder

See all competitors

Product	Company	Stage	Hype Score
Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcg	AstraZeneca	Approved	43
LLG783 + Placebo	Novartis	Phase 2	35
Azithromycin plus chloroquine + sulfadoxine-pyrimethamine	Pfizer	Phase 3	32
ataciguat (HMR1766) + placebo + cilostazol	Sanofi	Phase 2	35
Ad2/HIF-1α/VP16 + Ad2/HIF-1α/VP16 + Ad2/HIF-1α/VP16	Sanofi	Phase 2	35
SL650472, Clopidogrel	Sanofi	Phase 2	35
Givosiran	Alnylam Pharmaceuticals	Phase 1/2	29
Givosiran + 5-probe cocktail	Alnylam Pharmaceuticals	Phase 1	26
givosiran (ALN-AS1) + Sterile Normal Saline (0.9% NaCl)	Alnylam Pharmaceuticals	Phase 1	26
Sapropterin Dihydrochloride	BioMarin Pharmaceutical	Phase 2	32
Tetrahydrobiopterin 10 mg/kg + Tetrahydrobiopterin 20 mg/kg + L-Ascorbate + L-Arginine	BioMarin Pharmaceutical	Phase 1	33
Placebo + 375 mg CK-2017357 + 500 mg CK-2017357	Cytokinetics	Phase 2	32